Stock Market & Financial Investment News

News Breaks December 26, 2012 06:45 EDT AEGR Aegerion price target raised to $30 from $25 at Leerink Leerink raised its price target for Aegerion after the FDA approved Juxtapid. The firm reiterates an Outperform rating on Aegerion, noting the company obtained the broadest possible label possible for Juxtapid. News For AEGR From The Last 14 Days Check below for free stories on AEGR the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 12, 2013 07:20 EDT AEGR Aegerion price target raised to $88 from $69 at JPMorgan Subscribe for More Information June 11, 2013 07:42 EDT AEGR Boston Biotech Conferences to host a conference Subscribe for More Information June 7, 2013 09:32 EDT AEGR Aegerion price target raised to $100 from $58 at BofA/Merrill June 5, 2013 17:50 EDT AEGR Aegerion CEO says Juxtapid has approximately 18,000 potential patients Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.